The greatest disparity in BC-specific survival was observed in women with HR+ HER2− tumors, with Black women having a 50% ...

During a Case-Based Roundtable® event, Michael J. Birrer, MD, PhD, moderated a discussion on what factors affect the need for ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

A new innovative tool forecasts the severity of a patient’s diagnosis and its likelihood of recurrence. This latest ...

The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in combination with an aromatase ...

Breast cancer remains the most common invasive cancer diagnosed in women in the United States, accounting for about one in three new female cancers each ye | Cancer ...

Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer ...

Researchers have developed a new mechanism for predicting the aggressiveness of triple-negative breast cancer (TNBC). This ...

Groups Develop Request for Proposals for Research Grants Focused on Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations This collaboration seeks to address important mechanistic ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...